Negotiating with GLAS versus Oracle sales means handling two different rooms at once, where GLAS sets the compliance finding and sales converts it into a deal, and independent line by line review typically cuts the finding 60 to 80 percent before either room can price it.
Who is GLAS and who is sales?
GLAS, the Oracle Global Licensing and Advisory Services team formerly known as LMS, runs the audit under the audit clause in your Oracle Master Agreement, and the sales account team owns the commercial relationship and the renewal. They are different functions with different mandates. GLAS measures deployment against entitlement and produces a finding. Sales takes that finding and turns it into a purchase, a ULA renewal, an OCI commitment, or a Java subscription. Reading the two as one voice is the first mistake buyers make.
The reason the split matters is that an Oracle audit is a negotiation dressed up as an inspection, and the preliminary number GLAS produces is an opening position, not a bill. GLAS frames the finding in technical and contractual terms. Sales reframes it in commercial terms, where the same exposure becomes the reason to sign a larger deal. Knowing which room you are in tells you which argument lands.
Why does the difference change your strategy?
The difference changes your strategy because the two rooms respond to different evidence. With GLAS you argue measurement: core factor table math, options that were never deliberately used, virtualization scope, and Named User Plus counts against the minimums. With sales you argue value: what you will actually buy, on what timeline, and what your credible alternative is if the deal is wrong. Bring a commercial argument to GLAS and it bounces. Bring a technical argument to sales and it stalls.
Audits are also a sales channel, with roughly 20 to 30 percent of Oracle on premises license revenue estimated by analysts to flow from audits. That single fact explains why the finding rarely stays a pure compliance question. The buyer who keeps the technical dispute with GLAS and the commercial dispute with sales, and refuses to let one contaminate the other, keeps control of both.
What each room wants from you
| Dimension | GLAS | Sales |
|---|---|---|
| Mandate | Measure and find | Sell and renew |
| Currency | Compliance finding at list price | A signed commercial deal |
| Best argument against | Measurement and contract | Value and your alternative |
| What they over reach on | Script output and policy scope | Deal size and urgency |
GLAS wants a defensible measurement it can stand behind, so it leans on its own collection scripts and on policy papers that extend scope. Oracle collection scripts can overcount across virtualization layers, so script output is reviewed before submission, and running Oracle scripts at all is a decision rather than an obligation. Sales wants a signed deal and uses urgency, the threat of the full list price finding, and the offer of a renewal to get there.
How do the two rooms work together?
The two rooms work together by design: GLAS produces an inflated finding at list price, and sales arrives with the relief, a discount or a bundle that makes the finding disappear if you commit to something larger. The finding is the pressure and the deal is the release. Preliminary findings arrive inflated at list price precisely so the commercial offer feels like a saving against a number that was never realistic.
Understanding the choreography lets you slow it down. You resolve the measurement with GLAS first, on the evidence, and only then discuss commercial terms with sales against a corrected number. A buyer who lets sales price an uncorrected finding pays for exposure that independent review would have removed. The order is the leverage.
Why does the contract beat both rooms?
The contract beats both rooms because the policy document is not the contract. Many cluster wide virtualization claims and broad scope arguments rest on Oracle policy papers that are often weaker than the signed agreement, and contract language beats policy. When GLAS asserts scope and sales prices it, the signed Oracle Master Agreement and the ordering documents are the ground both have to stand on.
This is why the agreement is read before either conversation gets commercial. The audit clause, the definitions of the metrics, the territory and the entity scope, and any negotiated protections all bound what GLAS can find and what sales can sell. A finding that contradicts the contract is not a finding to be discounted, it is a finding to be removed.
What is the buyer move?
The buyer move is to separate the rooms and run them in order. Keep the technical and contractual dispute with GLAS, review the script output and the options evidence line by line, and settle the measurement on the facts. Then take the corrected number to sales and negotiate the commercial terms with a credible alternative in hand. Independent line by line review of findings typically cuts claims 60 to 80 percent, and most of that cut belongs in the GLAS room before sales ever quotes a price.
We position as an independent buyer side advisory with deep Oracle licensing expertise. In practice that means we hold the line on measurement with GLAS and on commercial value with sales, so neither room prices exposure that should not exist. Book a strategy call and we will map both rooms against your actual estate.
Where to go next
This piece links up to the Oracle Negotiation Guide. Keep reading across the cluster:
Book a strategy call to map GLAS and sales against your estate, or read the full Oracle Negotiation Guide.